Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGPU NYSE:MLSS NASDAQ:PAVM NASDAQ:PETV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGPUPredictive Oncology$5.67-5.0%$3.36$1.03▼$32.10$31.41M3.452.45 million shs236,825 shsMLSSMilestone Scientific$0.46-2.6%$0.30$0.22▼$1.05$36.77M0.971.55 million shs399,775 shsPAVMPAVmed$7.16+0.3%$9.57$6.00▼$28.44$7.13M0.64713,342 shs24,188 shsPETVPetVivo$0.80+2.4%$0.76$0.58▼$1.69$28.64M1.2711,282 shs11,792 shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGPUPredictive Oncology+0.67%+1.02%+25.42%+159.57%+596,999,900.00%MLSSMilestone Scientific+16.26%+51.29%+66.31%+77.99%-48.46%PAVMPAVmed+1.85%-13.98%-24.92%-33.89%-67.35%PETVPetVivo0.00%0.00%+18.26%-9.24%+26.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGPUPredictive Oncology$5.67-5.0%$3.36$1.03▼$32.10$31.41M3.452.45 million shs236,825 shsMLSSMilestone Scientific$0.46-2.6%$0.30$0.22▼$1.05$36.77M0.971.55 million shs399,775 shsPAVMPAVmed$7.16+0.3%$9.57$6.00▼$28.44$7.13M0.64713,342 shs24,188 shsPETVPetVivo$0.80+2.4%$0.76$0.58▼$1.69$28.64M1.2711,282 shs11,792 shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGPUPredictive Oncology+0.67%+1.02%+25.42%+159.57%+596,999,900.00%MLSSMilestone Scientific+16.26%+51.29%+66.31%+77.99%-48.46%PAVMPAVmed+1.85%-13.98%-24.92%-33.89%-67.35%PETVPetVivo0.00%0.00%+18.26%-9.24%+26.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGPUPredictive Oncology 1.00SellN/AN/AMLSSMilestone Scientific 3.00Buy$1.00118.82% UpsidePAVMPAVmed 2.00Hold$65.00807.82% UpsidePETVPetVivo 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PAVM, MLSS, AGPU, and PETV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026AGPUPredictive Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026PAVMPAVmed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)4/9/2026PAVMPAVmed Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$510.00 ➝ $65.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGPUPredictive Oncology$125.28K250.68N/AN/A$11.69 per share0.49MLSSMilestone Scientific$8.97M4.10N/AN/A$0.11 per share4.15PAVMPAVmed$71K100.44N/AN/A($2.42) per share-2.96PETVPetVivo$1.05M27.38N/AN/A($0.03) per share-26.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGPUPredictive Oncology-$233.10M-$12.62N/AN/AN/A-185,476.72%N/A-970.41%N/AMLSSMilestone Scientific-$6.93M-$0.06N/AN/AN/A-52.01%-60.26%-40.23%N/APAVMPAVmed$400K-$22.77N/AN/AN/A564.79%-242.99%-17.25%5/15/2026 (Estimated)PETVPetVivo-$10.95M-$0.38N/AN/AN/A-902.82%-4,813.07%-281.78%6/25/2026 (Estimated)Latest PAVM, MLSS, AGPU, and PETV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026PAVMPAVmed-$0.69N/AN/AN/A$0.07 millionN/A3/31/2026Q4 2025AGPUPredictive OncologyN/A$122.75N/A$122.75N/A$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAGPUPredictive OncologyN/AN/AN/AN/AN/AMLSSMilestone ScientificN/AN/AN/AN/AN/APAVMPAVmedN/AN/AN/AN/AN/APETVPetVivoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGPUPredictive OncologyN/A10.0210.02MLSSMilestone ScientificN/A2.851.86PAVMPAVmedN/A0.170.17PETVPetVivo0.020.420.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGPUPredictive Oncology9.04%MLSSMilestone Scientific5.79%PAVMPAVmed19.93%PETVPetVivo24.55%Insider OwnershipCompanyInsider OwnershipAGPUPredictive Oncology1.21%MLSSMilestone Scientific12.51%PAVMPAVmed5.80%PETVPetVivo10.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGPUPredictive Oncology305.54 million5.47 millionN/AMLSSMilestone Scientific3080.45 million58.61 millionOptionablePAVMPAVmed90996,000938,000OptionablePETVPetVivo2035.85 million19.06 millionNot OptionablePAVM, MLSS, AGPU, and PETV HeadlinesRecent News About These CompaniesPeer To Peer Network: PTOP's AI Partner Tier 1 AI, Signs Contract With OTCQX:PETV as Enterprise ClientApril 29, 2026 | finanznachrichten.dePTOP’s AI Partner Tier 1 AI, Signs Contract With OTCQX:PETV as Enterprise ClientApril 29, 2026 | usatoday.comPetVivo Holdings, Inc. to Present at the Market Movers Investor SummitApril 21, 2026 | newsfilecorp.comNPETVIVO HOLDINGS, INC. TO EXHIBIT AT THE ACVSMR SYMPOSIUM IN LEXINGTON, KENTUCKYMarch 19, 2026 | cincinnati.comCPetVivo Holdings: Balancing Ambitious Growth with Financial RealityFebruary 23, 2026 | newscase.comNPetVivo Holdings Inc (PETV) Q3 2026 Earnings Call Highlights: Strategic Partnerships and AI ...February 19, 2026 | finance.yahoo.comPetVivo Holdings, Inc.: PetVivo Reports Results for Third Quarter and First Nine Months of Fiscal 2026February 18, 2026 | finanznachrichten.dePetVivo Holdings, Inc. (OTC:PETV) Q3 2026 earnings call transcriptFebruary 18, 2026 | msn.comPetVivo Reports Results for Third Quarter and First Nine Months of Fiscal 2026February 18, 2026 | finance.yahoo.comPetVivo Holdings, Inc. (PETV) Q3 2026 Earnings Call TranscriptFebruary 17, 2026 | seekingalpha.comPETVIVO HOLDINGS, INC. TO EXHIBIT AT THE 2026 OCALA EQUINE CONFERENCE IN OCALA, FLORIDAFebruary 15, 2026 | azcentral.comAPetVivo Issues Correction and Replacement Press Release; Sets Fiscal Third Quarter 2026 Conference Call for Tuesday, February 17, 2026 at 5:00 p.m. ETFebruary 10, 2026 | globenewswire.comPetVivo Sets Fiscal Third Quarter 2026 Conference Call for Monday, February 16, 2026 at 5:00 p.m. ETFebruary 9, 2026 | globenewswire.comPetVivo Holdings, Inc. Announces Health Canada Acknowledgement of Spryng® as a Veterinary Medical DeviceJanuary 21, 2026 | finance.yahoo.comNew To The Street T.V. Commercials Break Digital RecordsJanuary 3, 2026 | newsobserver.comNPetVivo Holdings, Inc. Presenting at the 3rd Annual DealFlow Discovery ConferenceDecember 23, 2025 | accessnewswire.comAPetVivo.ai Breaks the Mold: Launches Video Explainer Because "Nobody Reads Tech Press Releases Anymore"December 16, 2025 | globenewswire.comPetVivo launches AI platform reducing vet client acquisition costsNovember 25, 2025 | msn.comPetVivo Launches AI Platform Reducing Veterinary Client Acquisition Costs by 50-89%November 25, 2025 | markets.businessinsider.comUPDATED: PetVivo AI, Inc. Launches AI Platform Reducing Veterinary Client Acquisition Costs by 50-90%November 25, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePAVM, MLSS, AGPU, and PETV Company DescriptionsPredictive Oncology NASDAQ:AGPU$5.67 -0.30 (-5.03%) Closing price 04:00 PM EasternExtended Trading$5.68 +0.01 (+0.19%) As of 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.Milestone Scientific NYSE:MLSS$0.46 -0.01 (-2.56%) Closing price 04:00 PM EasternExtended Trading$0.46 +0.00 (+0.44%) As of 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Milestone Scientific Inc., a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. In addition, the company offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances, and disposable injection handpiece for the tactile control during the injection. Further, it provides CompuFlo Epidural, a computer-controlled anesthesia system for use in various medical applications. Additionally, the company offers company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Roseland, New Jersey.PAVmed NASDAQ:PAVM$7.16 +0.02 (+0.28%) Closing price 03:59 PM EasternExtended Trading$7.28 +0.12 (+1.68%) As of 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.PetVivo NASDAQ:PETV$0.80 +0.02 (+2.37%) As of 03:40 PM EasternPetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
